It has been reported that point mutations in genes are responsible for various cancers, and the selective regulation of gene expression is an important factor in developing new types of anticancer drugs. To develop effective drugs for the regulation of point-mutated genes, we focused on photoreactive antisense oligonucleotides. Previously, we reported that photoreactive oligonucleotides containing 2′-O-psoralenylmethoxyethyl adenosine (2′-Ps-eom) showed drastic photoreactivity in a strictly sequence-specific manner. Here, we demonstrated the specific gene regulatory effects of 2′-Ps-eom on [12Val]K-ras mutant (GGT s→ GTT). Photo-cross-linking between target mRNAs and 2′-Ps-eom was sequence-specific, and the effect was UVA irradiation-dependent. Furthermore, 2′-Ps-eom was able to inhibit K-ras-immortalized cell proliferation (K12V) but not Vco cells that have the wild-type K-ras gene. These results suggest that the 2′-Ps-eom will be a powerful nucleic acid drug to inhibit the expression of disease-causing point mutation genes, and has great therapeutic potential in the treatment of cancer.
Get full access to this article
View all access options for this article.
References
1.
ADJEIA.A. (2001) . Blocking oncogenic ras signaling for cancer therapy. J. Natl. Cancer Inst. 93,1062–1074.
2.
AGRAWALS., TEMSAMAMIJ., GALBARAITHW., and TANGJ. (1995) . Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28,7–16.
3.
AGRAWALS., TEMSAMAMIJ., and TANGJ.Y. (1991) . Pharmacokinetics, biodistribution, and stability of oligonucleotides phosphorothioates in mice. Proc. Natl. Acad. Sci. USA. 88,7597–7599.
4.
ALMOGUERAC., SHIBATAD., FORRESTERK., MARTINJ., ARNHEIMN., and PERUCHOM. (1988) . Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 53,549–554.
5.
ANDERSONK.P., FOXM.C., BROWN-DRIVERV., MARTINM.J., and AZADR.F. (1996) . Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotides complementary to immediate-early RNA. Agents. Chemother. 40,2004–2011.
6.
AZADR.F., DRIVERV.B., TANAKAK., CROOKER.M., and ANDERSONK.P. (1993) . Antiviral activity of a phosphorothioate oligonucleotides complementary to RNA of the Human cytomegalovirus major immediate-early region. Antimicrob. Agents. Chemother. 37,1945–1954.
BIANCOR., MELISID., CIARDIELLOF., and TORTORAG. (2006) . Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer, 42,290–294.
9.
BOSJ.L. (1989) . ras oncogenes in human cancer: a review. Cancer Res. 49,4682–4689.
10.
BRUMMELKAMPT.R., BERNARDSR., and AGAMIR. (2002) . Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2,243–247.
11.
CAPELLAG., CRONAUER-MITRAS., PEINADOM.A., and PERUCHOM. (1991) . Frequency and spectrum of mutations at codon 12 and 13 of the c-K-ras gene in human tumors. Environ. Health. Persp. 93, 125–131.
12.
CIMINOG.D., GAMPERH.B., ISAACSS., and HEARSTJ. (1985) . Psoralens as photoactive probes of nucleic acid structure and function: organic chemistry, photochemistry, and biochemistry. Ann. Rev. Biochem. 54,1151–1193.
13.
DASHP., LOTANI., KNAPPI., KANDELE.R., and GOELETP. (1987) . Selective elimination of mRNAs in vivo: complementary oligonucleotides promote RNA degradation by an RNase H-like activity. Proc. Natl. Acad. Sci. USA. 84,7896–7900.
14.
DEANN.M., and BANNETTC.F. (2003) . Antisense oligonucleotides-based therapeutics for cancer. Oncogene. 22,9087–9096.
15.
GILLEH., and DOWNWARDJ. (1999) . Multiple ras effector pathway contribute to G1 cell cycle progression. J. Biol. Chem. 274,22033–22040.
16.
GLEAVEM.E., and MONIAB.P. (2005) . Antisense therapy for cancer. Nat. Rev. Cancer. 5,468–479.
17.
HAEUPTLEM.T., FRANKR., and DOBBERSTEINB. (1986) . Translation arrest by oligonucleotides complementary to mRNA coding sequences yields polypeptides of predetermined length. Nucleic Acids Res. 14,1427–1448.
18.
HIGUCHIM., SAKAMOTOT., KOBORIA., and MURAKAMIA. (2006) . Properties of novel antisense oligonucleotides containing 2′-O-modified adenosine with a photo-reactive group. Nucleic Acids Symp. Ser. 50, 301–302.
19.
HIGUCHIM., YAMAYOSHIA., KOBORIA., and MURAKAMIA. (2007a ). Selective regulation of mutant K-ras mRNA expression by photo-cross-linking antisense oligonucleotides. Nucleic Acids Symp. Ser. 51,443–444.
20.
HIGUCHIM., YAMAYOSHIA., YAMAGUCHIT., IWASER., YAMAOKAT., and MURAKAMIA. (2007b ). Selective photo-cross-linking of 2′-O-psoralen-conjugated oligonucleotides with RNAs having point mutations. Nucleosides Nucleotides Nucleic Acids
26, 277–290.
21.
HOLLSTEINM., SIDRANSKYD., VOGELSTEINB., and HARRISC.C. (1991) . p53 mutations in human cancers. Science, 253,49–53.
22.
JACKSONA.L., BARTZS.R., SCHELTERJ., KOBAYASHIS.V., BURCHARDJ., MAOM., LIB., CAVETG., and LINSLEYP.S. (2003) . Expression profiling reveals off target gene regulation by RNAi. Nat. Biol. 21,635–637.
23.
KATOK., UENOY., KATOK., HACHIYAT., NISHIDAJ., and WAKEN. (1997) . Contribution of enhanced transcriptional activation by ER to [12Val]K-ras mediated NIH3T3 cell transformation. Oncogene, 15,3037–3046.
24.
KEANJ.M., MURAKAMIA., BLAKEK.R., CUSHMANC.D., and MILLERP.S. (1988) . Photochemical cross-linking of psoralen-derivatized oligonucleoside methylphosphonates to Rabbit globin messenger RNA. Biochemistry, 27,9113–9121.
25.
KURRECKJ. (2003) . Antisense technologies. Eur. J. Biochem. 270,1628–1644.
26.
LEEB.L., MURAKAMIA., BLAKEK.R., LINS.B., and MILLERP.S. (1988) . Interaction of psoralen-derivatized oligonucleoside methylphosphonates with single-stranded DNA. Biochemistry, 27,3197–3203.
27.
MANOHARANM. (2002) . Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 12,103–128.
28.
MURAKAMIA., YAMAYOSHIA., IWASER., NISHIDAJ., YAMAOKAT., and WAKEN. (2001) . Photodynamic antisense regulation of human cervical carcinoma cell growth using psoralen-conjugated oligo(nucleoside phosphorothioate). Eur. J. Pharma. Sci. 13,25–34.
29.
NINOMIYAY., KATOK., TAKAHASHIA., UEOKAY., KIMIKIHARAT., ARIMAT., MATSUDAT., KATOH., NISHIDAJ., and WAKEN. (2004) . K-ras and H-ras activation promote distinct consequences on endometrial cell survival. Cancer Res. 64,2759–2765.
30.
OHD.H., KINGB.A., BOXERS.G., and HANAWALTP.C. (2001) . Spatially localized generation of nucleotide sequence-specific DNA damage. Proc. Natl. Acad. Sci. USA. 98,11271–11276.
31.
OHD.H., STANLEYR.J., LINM., HOEFFLERW.K., BOXERS.G., BERNSM.W., and BAUERE.A. (1997) . Two-photon excitation of 4′-hydroxymethyl-4,5′-8-trimethylpsoralen. Photochem. Photobiol. 65, 91–95.
32.
SAISON-BEHMOARAST., TOCQUEB., REYI., CHASSIGNOLM., THOUONGN.T., and HELENEC. (1991) . Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 10,1111–1118.
33.
SCACHERIP.C., ROZENBLATT-ROSENO., CAPLENN.J., WOLFSBERGT.G., UMAYAML., LEEJ.C., HUGHESC.M., SHANMUGAMK.S., BHATTACHARJEEA., MEYERSONM., and COLLINSF.S. (2004) . Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl. Acad. Sci. USA. 101,1892–1897.
34.
SMITV.T.H.B.M., BOOTA.J.M., SMITSA.M.M., FLEURENG.J., CORNELISSEC.J., and BOSJ.L. (1988) . KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16,7773–7782.
35.
STEINC.A., and CHENGY.C. (1993) . Antisense oligonucleotides as therapeutic agents is the bullet really magical?. Science, 261,1004–1012.
36.
TAKESHITAF., and OCHIYAT. (2006) . Therapeutic potential of RNA interference against cancer. Cancer Sci. 97,689–696.
37.
TAKUWAN., and TAKUWAY. (2001) . Regulation of cell cycle molecules by the ras effecter system. Mol. Cell. Endocrinol. 177,25–33.
38.
TRAHEYM., and MCCORMICKF. (1987) . A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science, 238,542–545.
39.
YAMAMOTOF., and PERUCHOM. (1984) . Activation of a human c-K-ras oncogene. Nucleic Acids Res. 12,8873–8885.
40.
YAMAYOSHIA., KATOK., SUGAS., ICHINOEA., ARIMAT., MATSUDAT., KATOH., MURAKAMIA., and WAKEN. (2007) . Specific apoptosis induction in human papillomavirus-positive cervical carcinoma cells by photodynamic antisense regulation. Oligonucleotide, 17,66–79.
41.
ZHANGZ., JIANGG., YANGF., and WANGJ. (2006) . Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells. Cancer Biol. Ther. 5,1481–1486.
